Developer docs
API playgroundTry for free, no card

Search company profiles

SkylineDx

Full company profile

uuid0000yw5

Namestring
SkylineDx
Legal namestring
SkylineDx B.V.
Websiteurl
skylinedx.com
Company typeenum
Private
Founded yearint
2013
Descriptiontext

SkylineDx is a privately held molecular diagnostics company headquartered in Rotterdam, Netherlands, founded in 2013 to commercialize academically discovered biomarkers into clinically validated diagnostic assays. The company operates two clinical laboratories — its ISO 13485:2016-certified headquarters in Rotterdam and a CAP/CLIA-certified laboratory in San Diego, California — enabling it to deliver tests as laboratory-developed tests (LDTs) in the United States and as CE-IVD/UKCA-marked kits in Europe.

The company's core technology is the CP-GEP (Clinicopathologic and Gene Expression Profile) architecture, which combines clinical variables with gene expression profiling data into a single integrated algorithm that stratifies patients into binary High or Low Risk categories. Its two commercialized products are Merlin CP-GEP for cutaneous melanoma (predicting sentinel lymph node biopsy metastasis risk) and SKY92 (marketed as MMprofiler in Europe) for multiple myeloma prognosis. Both products are deployed on qRT-PCR and microarray platforms. The Merlin test became the first and only molecular diagnostic recognized by the NCCN Clinical Practice Guidelines in Oncology (Version 1.2026) for assessing metastatic risk in select early-stage melanoma patients. Pipeline programs include SCCore GEP for cutaneous squamous cell carcinoma and KiDs-GEP for early diagnosis of Kawasaki disease, supported by research collaborations with Mayo Clinic, Erasmus MC, Imperial College London, UC San Diego, and UCSF.

SkylineDx monetizes through fee-for-service diagnostic testing ordered by healthcare providers, with revenue generated via its direct laboratory testing channel in the U.S. and partner-distributed CE-IVD kits in Europe. Pricing is quote-based and not publicly disclosed. The go-to-market is enterprise field sales targeting academic medical centers, leading oncology centers, and dermatology practices, with the NCCN guideline inclusion serving as the primary adoption lever. The company employs a team of over 70 international experts across scientific, bioinformatics, lab operations, commercial, QA/RA, and administrative functions, and was awarded the 2025 BioTech Breakthrough Award for 'Diagnostics Company of the Year.'

Short descriptiontext

SkylineDx is a Rotterdam-based molecular diagnostics company that develops and commercializes gene expression profile tests for oncology and inflammatory diseases, offering Merlin CP-GEP for cutaneous melanoma risk stratification and SKY92 for multiple myeloma prognosis to clinicians globally.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
51–100
akta.pro rankint
HeadquartersRotterdam, Netherlands
HQ citystring
Rotterdam
HQ countrystring
Netherlands
HQ regionstring
Europe
Markets served

Serves global market

Offices2 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
molecular diagnostics services, gene expression profiling, melanoma diagnostic testing, multiple myeloma prognosis, clinical laboratory diagnostics
Industry3 codes
PRIMARYHLAAALAE
Oncology Diagnostics (tumor profiling, MRD, liquid biopsy)
SECONDARYHLAAAMAF
Prognostic & Risk Stratification Biomarkers (disease progression, recurrence risk)
Healthcare & Life Sciences/Biotechnology & Biologics/Biomarkers and Companion Diagnostics
SECONDARYHLAAAMAC
Clinical Biomarker Testing Services (central labs, trial enrollment/monitoring assays)
Healthcare & Life Sciences/Biotechnology & Biologics/Biomarkers and Companion Diagnostics
NAICS code2 codes
  • Medical Laboratories621511
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
SIC code1 code
  • Services-Medical Laboratories8071
Product category
Molecular Diagnostics
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model1 record
1Molecular Diagnostic Testing Services
TypeOne Time License
Description

SkylineDx operates CAP/CLIA-certified clinical laboratories in San Diego (USA) and Rotterdam (Netherlands) providing diagnostic testing services. Tests are marketed as laboratory-developed tests (LDT) in the USA and CE-IVD/UKCA marked kits in Europe. Revenue is generated through test ordering by healthcare providers and clinical institutions.

skylinedx.com
Marketing channels6 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels3 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components6 values
Technology or R&D, Personnel, Operations, Marketing or Sales, Infrastructure, Supply Chain
GTM typeB2B
B2B
Offering typeServices
Services
Brand1 of 4 records shown
1Merlin Test / Merlin Assay / Merlin CP-GEP
Description

A gene expression profile test for cutaneous melanoma that predicts sentinel lymph node metastasis risk. Marketed as Merlin Assay in EU (CE-IVD) and Merlin CP-GEP in the USA (LDT).

skylinedx.com
+3 more records
Core offering1 text field

SkylineDx develops and commercializes signature-based molecular diagnostic tests that analyze patient gene expression combined with clinicopathologic variables to stratify disease risk. Its commercial portfolio includes the Merlin CP-GEP Test for cutaneous melanoma (predicting sentinel lymph node metastasis risk) and the SKY92 test for multiple myeloma prognosis. Tests are delivered through the company's CAP/CLIA laboratory in San Diego (as Laboratory Developed Tests in the US) and as CE-IVD/UKCA marked kits (Merlin Assay, MMprofiler) in Europe. The company also runs a STRIX innovation engine that evaluates and in-licenses new biomarkers from academic partners for development into commercial diagnostic assays.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 9 values shown
  • Merlin CP-GEP reduced SLNB rates by over 40% in Danish multicenter validation study
+8 more records
Product overview1 text field

SkylineDx is a molecular diagnostics company offering two commercially available genomic assay tests: the Merlin CP-GEP Test for cutaneous melanoma risk stratification and the SKY92 test for multiple myeloma prognosis. The Merlin CP-GEP combines clinicopathologic features with gene expression profiling to predict sentinel lymph node metastasis, enabling clinicians to identify low-risk patients who may forgo invasive surgery. SKY92 analyzes 92 genes in malignant plasma cells to identify high-risk multiple myeloma patients requiring intensified treatment. The company operates research programs (Falcon for dermato-oncology, Panthera for hematology, Delphia for infectious/inflammatory diseases) and maintains an innovation engine (STRIX) to evaluate and license new biomarkers. Products are available in both the US (as LDTs) and Europe (CE-IVD/UKCA marked).

Product and service3 records
1Merlin CP-GEP Test (Merlin Test / Merlin Assay)
CategoryMolecular Diagnostic Test (Melanoma)
Description

A clinicopathologic and gene expression profile (CP-GEP) test for cutaneous melanoma that predicts sentinel lymph node metastasis risk. It combines clinicopathologic variables with gene expression profiling to stratify patients into High or Low Risk categories, enabling identification of patients who may safely forgo invasive sentinel lymph node biopsy. Developed with Mayo Clinic; commercially available in the US as an LDT and in the EU/UK as a CE-IVD/UKCA marked Merlin Assay kit.

2SKY92 (MMprofiler)
CategoryMolecular Diagnostic Test (Multiple Myeloma)
Description

A gene expression profiling test that analyzes 92 genes in malignant plasma cells to determine multiple myeloma prognosis and risk stratification. Identifies high-risk myeloma patients who may require more intensive treatment. Developed with Erasmus MC; commercially available in the US as an LDT and in the EU as a CE-IVD/UKCA marked MMprofiler assay kit.

3KiDs-GEP Classifier (Kawasaki Disease)
Scale indicator6 records

Each record includes

Type, Value, Description, Source

Partnership5 partners
Strategic tierCoreTypeStrategic or Co-development Partner
Description

Mayo Clinic co-developed the CP-GEP (Merlin CP-GEP) algorithm with SkylineDx. The Merlin CP-GEP test was developed through this collaboration and is exclusively licensed to SkylineDx. Mayo Clinic is a key partner in clinical validation and ongoing research collaboration.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

Erasmus MC is the licensor of the SKY92 gene expression signature to SkylineDx. The partnership has enabled the development and commercialization of the SKY92 multiple myeloma prognostic test. Erasmus MC is also a collaboration partner in the Falcon R&D Program for dermato-oncology and the international research on cutaneous squamous cell carcinoma.

Strategic tierSecondaryTypeStrategic or Co-development Partner
Description

Imperial College London collaborates with SkylineDx on the Delphia R&D Program for Kawasaki disease diagnostics. Together with UC San Diego School of Medicine, they developed the KiDs-GEP classifier for early diagnosis of Kawasaki disease.

Strategic tierSecondaryTypeStrategic or Co-development Partner
Description

UCSF is part of an international research collaboration with SkylineDx and Erasmus Medical Center on cutaneous squamous cell carcinoma. The collaboration conducted the largest omics characterization of CSCC to date, involving RNA-sequencing of 366 tumors and whole-exome sequencing of 147 tumors.

Strategic tierSecondaryTypeStrategic or Co-development Partner
Description

BioInvent has worked with SkylineDx since 2019 on research projects focused on advancing personalized care in cancer. SkylineDx has provided molecular diagnostics expertise supporting BioInvent's development of novel immuno-modulatory antibodies for cancer therapies.

Recent move8 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Castle Biosciences' DecisionDx-Melanoma is the most direct U.S. competitor to Merlin CP-GEP for cutaneous melanoma risk stratification. Both companies sell gene-expression-based molecular prognostic tests targeting the same dermatology and surgical oncology call points, with similar LDT-based U.S. commercialization models.

TypeBroad incumbent
Description

Veracyte operates a portfolio of genomic diagnostics including Prosigna (breast cancer) and the Decipher urologic oncology tests. It is a broader incumbent in oncology molecular diagnostics with established U.S. sales infrastructure and reimbursement track record relevant to scaling SkylineDx-style GEP products.

TypeBroad incumbent
Description

NeoGenomics is a large clinical oncology laboratory providing a broad menu of molecular and hematology-oncology testing services, including multiple-myeloma prognostic workups. It competes indirectly with SKY92 and is a relevant reference for commercial scale and reimbursement strategy in the same call points.

TypeDirect peer
Description

Adaptive Biotechnologies' clonoSEQ is an FDA-cleared MRD test for multiple myeloma and other lymphoid malignancies. It directly overlaps SKY92 in the multiple-myeloma prognostic and treatment-decision workflow, addressing the same hematology customer segment with a different but related molecular approach.

TypeBroad incumbent
Description

Natera operates Signatera (tumor-informed MRD) and a broader reproductive and oncology testing menu. Its oncology commercial footprint and LDT-to-FDA-cleared hybrid regulatory model are directly comparable to SkylineDx's strategy of building guideline-anchored molecular diagnostic franchises.

TypeBroad incumbent
Description

Exact Sciences owns Oncotype DX (breast, prostate, colon cancer recurrence) and Cologuard, making it a broad incumbent in cancer molecular diagnostics. The Oncotype DX franchise in particular is a model for how a gene-expression-based oncology test scales commercially once reimbursement and guideline inclusion are achieved.

TypeBroad incumbent
Description

Guardant Health is a liquid-biopsy leader with Guardant360 and Guardant Reveal. While technology-different (cell-free DNA vs. tissue GEP), it competes for the same oncology precision-medicine budget and shares SkylineDx's need to secure guideline inclusion, payer coverage, and physician adoption across multiple solid tumors.

TypeEmerging player
Description

Personalis is a cancer genomics company with its NeXT Personal MRD test and tumor profiling offerings, comparable in size and stage to SkylineDx. Both companies are building molecular diagnostic franchises in oncology with a focus on proprietary algorithms and prospective clinical validation studies.

TypeBroad incumbent
Description

Myriad Genetics offers a broad hereditary and tumor-profiling testing menu (BRACAnalysis, myChoice HRD, etc.) and is a relevant broad incumbent in molecular diagnostics. Its experience navigating reimbursement and regulatory pathways informs comparable scale-up strategies for niche GEP players like SkylineDx.

TypeBroad incumbent
Description

Foundation Medicine, a Roche subsidiary, provides comprehensive genomic profiling (FoundationOne CDx) and is a broad incumbent in oncology molecular diagnostics. While focused on broad tumor profiling rather than narrow GEP stratification, it competes for the same oncology precision-medicine budget and physician mind-share.

Market position
Strengths4 records

Each record includes

Headline, Details, Source

Weaknesses4 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers2 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment4 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI capability3 records

Each record includes

Type, Description, Source

AI maturity
App detail

Has app

Feature6 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles14 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

Subsidiaries1 record

Each record includes

Name, Acquired on, Relationship type, Type, Business focus

Compliance3 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds3 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors2 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment1 record

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

SkylineDx

Molecular Diagnosticsskylinedx.com

SkylineDx is a Rotterdam-based molecular diagnostics company that develops and commercializes gene expression profile tests for oncology and inflammatory diseases, offering Merlin CP-GEP for cutaneous melanoma risk stratification and SKY92 for multiple myeloma prognosis to clinicians globally.

What SkylineDx does

SkylineDx is a privately held molecular diagnostics company headquartered in Rotterdam, Netherlands, founded in 2013 to commercialize academically discovered biomarkers into clinically validated diagnostic assays. The company operates two clinical laboratories — its ISO 13485:2016-certified headquarters in Rotterdam and a CAP/CLIA-certified laboratory in San Diego, California — enabling it to deliver tests as laboratory-developed tests (LDTs) in the United States and as CE-IVD/UKCA-marked kits in Europe.

The company's core technology is the CP-GEP (Clinicopathologic and Gene Expression Profile) architecture, which combines clinical variables with gene expression profiling data into a single integrated algorithm that stratifies patients into binary High or Low Risk categories. Its two commercialized products are Merlin CP-GEP for cutaneous melanoma (predicting sentinel lymph node biopsy metastasis risk) and SKY92 (marketed as MMprofiler in Europe) for multiple myeloma prognosis. Both products are deployed on qRT-PCR and microarray platforms. The Merlin test became the first and only molecular diagnostic recognized by the NCCN Clinical Practice Guidelines in Oncology (Version 1.2026) for assessing metastatic risk in select early-stage melanoma patients. Pipeline programs include SCCore GEP for cutaneous squamous cell carcinoma and KiDs-GEP for early diagnosis of Kawasaki disease, supported by research collaborations with Mayo Clinic, Erasmus MC, Imperial College London, UC San Diego, and UCSF.

SkylineDx monetizes through fee-for-service diagnostic testing ordered by healthcare providers, with revenue generated via its direct laboratory testing channel in the U.S. and partner-distributed CE-IVD kits in Europe. Pricing is quote-based and not publicly disclosed. The go-to-market is enterprise field sales targeting academic medical centers, leading oncology centers, and dermatology practices, with the NCCN guideline inclusion serving as the primary adoption lever. The company employs a team of over 70 international experts across scientific, bioinformatics, lab operations, commercial, QA/RA, and administrative functions, and was awarded the 2025 BioTech Breakthrough Award for 'Diagnostics Company of the Year.'

SkylineDx firmographics

Firmographics
Name
SkylineDx
Legal name
SkylineDx B.V.
Website
https://skylinedx.com
Company type
Private
Founded year
2013
Operating status
Operating
Headcount range
51–100 employees
Short description
SkylineDx is a Rotterdam-based molecular diagnostics company that develops and commercializes gene expression profile tests for oncology and inflammatory diseases, offering Merlin CP-GEP for cutaneous melanoma risk stratification and SKY92 for multiple myeloma prognosis to clinicians globally.
Ownership category
akta.pro rank

SkylineDx industry classification

Industry
Product category
Molecular Diagnostics
NAICS
Medical Laboratories (621511), Research and Development in Biotechnology (except Nanobiotechnology) (541714)
SIC
Services-Medical Laboratories (8071)
akta.pro industry
PRIMARYHLAAALAE
Oncology Diagnostics (tumor profiling, MRD, liquid biopsy)
SECONDARYHLAAAMAF
Prognostic & Risk Stratification Biomarkers (disease progression, recurrence risk)
Healthcare & Life Sciences/Biotechnology & Biologics/Biomarkers and Companion Diagnostics
SECONDARYHLAAAMAC
Clinical Biomarker Testing Services (central labs, trial enrollment/monitoring assays)
Healthcare & Life Sciences/Biotechnology & Biologics/Biomarkers and Companion Diagnostics

Keywords

  • Molecular diagnostics services
  • Gene expression profiling
  • Melanoma diagnostic testing
  • Multiple myeloma prognosis
  • Clinical laboratory diagnostics

Where SkylineDx is headquartered

Location

Headquarters

HQ city
Rotterdam
HQ country
Netherlands
HQ region
Europe

Offices2 records

Markets served

SkylineDx business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Technology or R&D, Personnel, Operations, Marketing or Sales, Infrastructure, Supply Chain

Revenue model

  1. Molecular Diagnostic Testing Services: SkylineDx operates CAP/CLIA-certified clinical laboratories in San Diego (USA) and Rotterdam (Netherlands) providing diagnostic testing services. Tests are marketed as laboratory-developed tests (LDT) in the USA and CE-IVD/UKCA marked kits in Europe. Revenue is generated through test ordering by healthcare providers and clinical institutions.

Go-to-market motion1 record

Distribution channels3 records

Marketing channels6 records

SkylineDx product offering

Product offering

Core offering

SkylineDx develops and commercializes signature-based molecular diagnostic tests that analyze patient gene expression combined with clinicopathologic variables to stratify disease risk. Its commercial portfolio includes the Merlin CP-GEP Test for cutaneous melanoma (predicting sentinel lymph node metastasis risk) and the SKY92 test for multiple myeloma prognosis. Tests are delivered through the company's CAP/CLIA laboratory in San Diego (as Laboratory Developed Tests in the US) and as CE-IVD/UKCA marked kits (Merlin Assay, MMprofiler) in Europe. The company also runs a STRIX innovation engine that evaluates and in-licenses new biomarkers from academic partners for development into commercial diagnostic assays.

Product overview

SkylineDx is a molecular diagnostics company offering two commercially available genomic assay tests: the Merlin CP-GEP Test for cutaneous melanoma risk stratification and the SKY92 test for multiple myeloma prognosis. The Merlin CP-GEP combines clinicopathologic features with gene expression profiling to predict sentinel lymph node metastasis, enabling clinicians to identify low-risk patients who may forgo invasive surgery. SKY92 analyzes 92 genes in malignant plasma cells to identify high-risk multiple myeloma patients requiring intensified treatment. The company operates research programs (Falcon for dermato-oncology, Panthera for hematology, Delphia for infectious/inflammatory diseases) and maintains an innovation engine (STRIX) to evaluate and license new biomarkers. Products are available in both the US (as LDTs) and Europe (CE-IVD/UKCA marked).

Differentiator

Problem solved

Functional benefit

Brands

  • Merlin Test / Merlin Assay / Merlin CP-GEP: A gene expression profile test for cutaneous melanoma that predicts sentinel lymph node metastasis risk. Marketed as Merlin Assay in EU (CE-IVD) and Merlin CP-GEP in the USA (LDT).
  • SKY92 / MMprofiler
  • CP-GEP
  • KiDs-GEP

Products and services

  • Merlin CP-GEP Test (Merlin Test / Merlin Assay) A clinicopathologic and gene expression profile (CP-GEP) test for cutaneous melanoma that predicts sentinel lymph node metastasis risk. It combines clinicopathologic variables with gene expression profiling to stratify patients into High or Low Risk categories, enabling identification of patients who may safely forgo invasive sentinel lymph node biopsy. Developed with Mayo Clinic; commercially available in the US as an LDT and in the EU/UK as a CE-IVD/UKCA marked Merlin Assay kit.
  • SKY92 (MMprofiler) A gene expression profiling test that analyzes 92 genes in malignant plasma cells to determine multiple myeloma prognosis and risk stratification. Identifies high-risk myeloma patients who may require more intensive treatment. Developed with Erasmus MC; commercially available in the US as an LDT and in the EU as a CE-IVD/UKCA marked MMprofiler assay kit.
  • KiDs-GEP Classifier (Kawasaki Disease)

Quantifiable outcome

  • Merlin CP-GEP reduced SLNB rates by over 40% in Danish multicenter validation study
  • +8 more outcomes

Companies that use SkylineDx

Customer profile

Named customers2 records

Segments4 records

Ideal customer profiles3 records

SkylineDx technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

AI capability3 records

Feature6 records

SkylineDx partnerships and signals

Strategic signal

Partnerships

Five partnerships are on record, tiered core and secondary.

  • Mayo Clinic (USA)coreStrategic or Co-development PartnerMayo Clinic co-developed the CP-GEP (Merlin CP-GEP) algorithm with SkylineDx. The Merlin CP-GEP test was developed through this collaboration and is exclusively licensed to SkylineDx. Mayo Clinic is a key partner in clinical validation and ongoing research collaboration.
  • Erasmus Medical Center (Rotterdam, Netherlands)coreStrategic or Co-development PartnerErasmus MC is the licensor of the SKY92 gene expression signature to SkylineDx. The partnership has enabled the development and commercialization of the SKY92 multiple myeloma prognostic test. Erasmus MC is also a collaboration partner in the Falcon R&D Program for dermato-oncology and the international research on cutaneous squamous cell carcinoma.
  • Imperial College London (UK)secondaryStrategic or Co-development PartnerImperial College London collaborates with SkylineDx on the Delphia R&D Program for Kawasaki disease diagnostics. Together with UC San Diego School of Medicine, they developed the KiDs-GEP classifier for early diagnosis of Kawasaki disease.
  • University of California, San Francisco (UCSF)secondaryStrategic or Co-development PartnerUCSF is part of an international research collaboration with SkylineDx and Erasmus Medical Center on cutaneous squamous cell carcinoma. The collaboration conducted the largest omics characterization of CSCC to date, involving RNA-sequencing of 366 tumors and whole-exome sequencing of 147 tumors.
  • BioInvent International ABsecondaryStrategic or Co-development PartnerBioInvent has worked with SkylineDx since 2019 on research projects focused on advancing personalized care in cancer. SkylineDx has provided molecular diagnostics expertise supporting BioInvent's development of novel immuno-modulatory antibodies for cancer therapies.

Scale indicators6 records

Recent moves8 records

Expansion highlights6 records

SkylineDx competitors and assessment

Company assessment

Direct peers

  • Castle Biosciences: Castle Biosciences' DecisionDx-Melanoma is the most direct U.S. competitor to Merlin CP-GEP for cutaneous melanoma risk stratification. Both companies sell gene-expression-based molecular prognostic tests targeting the same dermatology and surgical oncology call points, with similar LDT-based U.S. commercialization models.
  • Adaptive Biotechnologies: Adaptive Biotechnologies' clonoSEQ is an FDA-cleared MRD test for multiple myeloma and other lymphoid malignancies. It directly overlaps SKY92 in the multiple-myeloma prognostic and treatment-decision workflow, addressing the same hematology customer segment with a different but related molecular approach.

Broad incumbents

  • Veracyte: Veracyte operates a portfolio of genomic diagnostics including Prosigna (breast cancer) and the Decipher urologic oncology tests. It is a broader incumbent in oncology molecular diagnostics with established U.S. sales infrastructure and reimbursement track record relevant to scaling SkylineDx-style GEP products.
  • NeoGenomics: NeoGenomics is a large clinical oncology laboratory providing a broad menu of molecular and hematology-oncology testing services, including multiple-myeloma prognostic workups. It competes indirectly with SKY92 and is a relevant reference for commercial scale and reimbursement strategy in the same call points.
  • Natera: Natera operates Signatera (tumor-informed MRD) and a broader reproductive and oncology testing menu. Its oncology commercial footprint and LDT-to-FDA-cleared hybrid regulatory model are directly comparable to SkylineDx's strategy of building guideline-anchored molecular diagnostic franchises.
  • Exact Sciences: Exact Sciences owns Oncotype DX (breast, prostate, colon cancer recurrence) and Cologuard, making it a broad incumbent in cancer molecular diagnostics. The Oncotype DX franchise in particular is a model for how a gene-expression-based oncology test scales commercially once reimbursement and guideline inclusion are achieved.
  • Guardant Health: Guardant Health is a liquid-biopsy leader with Guardant360 and Guardant Reveal. While technology-different (cell-free DNA vs. tissue GEP), it competes for the same oncology precision-medicine budget and shares SkylineDx's need to secure guideline inclusion, payer coverage, and physician adoption across multiple solid tumors.
  • Myriad Genetics: Myriad Genetics offers a broad hereditary and tumor-profiling testing menu (BRACAnalysis, myChoice HRD, etc.) and is a relevant broad incumbent in molecular diagnostics. Its experience navigating reimbursement and regulatory pathways informs comparable scale-up strategies for niche GEP players like SkylineDx.
  • Foundation Medicine: Foundation Medicine, a Roche subsidiary, provides comprehensive genomic profiling (FoundationOne CDx) and is a broad incumbent in oncology molecular diagnostics. While focused on broad tumor profiling rather than narrow GEP stratification, it competes for the same oncology precision-medicine budget and physician mind-share.

Emerging players

  • Personalis: Personalis is a cancer genomics company with its NeXT Personal MRD test and tumor profiling offerings, comparable in size and stage to SkylineDx. Both companies are building molecular diagnostic franchises in oncology with a focus on proprietary algorithms and prospective clinical validation studies.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat5 records

Key highlights7 records

Customer concentration

SkylineDx social profiles

Digital presence

SkylineDx compliance and trust

Trust signal

Compliance3 records

SkylineDx financial estimates

Financial estimate

Revenue estimate

Valuation estimate

SkylineDx leadership team

Management profile

Number of profiles

Profiles14 records

SkylineDx subsidiaries and ownership

Company hierarchy

Subsidiaries1 record

SkylineDx funding detail

Funding detail

Funding overview

Funding rounds3 records

Investors2 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

SkylineDx M&A and investment

M&A and investment

M&A

Investments1 record

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about SkylineDx

What does SkylineDx do?

SkylineDx develops and commercializes signature-based molecular diagnostic tests that analyze patient gene expression combined with clinicopathologic variables to stratify disease risk. Its commercial portfolio includes the Merlin CP-GEP Test for cutaneous melanoma (predicting sentinel lymph node metastasis risk) and the SKY92 test for multiple myeloma prognosis. Tests are delivered through the company's CAP/CLIA laboratory in San Diego (as Laboratory Developed Tests in the US) and as CE-IVD/UKCA marked kits (Merlin Assay, MMprofiler) in Europe. The company also runs a STRIX innovation engine that evaluates and in-licenses new biomarkers from academic partners for development into commercial diagnostic assays.

Is SkylineDx a public or private company?

SkylineDx is a private company. It is classified as venture growth investor backed and is currently operating.

When was SkylineDx founded?

SkylineDx was founded in 2013. It employs 51 to 100 people.

Where is SkylineDx based?

SkylineDx is headquartered in Rotterdam, Netherlands, in the Europe region.

How does SkylineDx make money?

One revenue line is on record: molecular Diagnostic Testing Services.

Who are SkylineDx's main competitors?

Direct peers on record are Castle Biosciences and Adaptive Biotechnologies. Broad incumbents are Veracyte, NeoGenomics, Natera, Exact Sciences, Guardant Health, Myriad Genetics and Foundation Medicine. Personalis is listed as an emerging player.

Does SkylineDx have an API?

No public API is recorded for SkylineDx.

What industry is SkylineDx in?

SkylineDx's product category is Molecular Diagnostics. Its primary akta.pro industry code is HLAAALAE, Oncology Diagnostics (tumor profiling, MRD, liquid biopsy), with a secondary code of HLAAAMAF, Prognostic & Risk Stratification Biomarkers (disease progression, recurrence risk). Its NAICS code is 621511 and its SIC code is 8071.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
citybizSkylineDx Named “Diagnostics Company of the Year” by BioTech Breakthrough for a Second Straight YearSkylineDx was named Diagnostics Company of the Year for a second consecutive year in the 2026 BioTech Breakthrough Awards. The recognition follows NCCN guideline updates and FDA Breakthrough Device Designation for its Merlin CP-GEP melanoma test. The company is expanding its clinical, sales, and marketing teams.PR NewswireSkylineDx Wins 2026 BioTech Breakthrough Award for "Diagnostics Company of the Year" for Second Consecutive YearSkylineDx won Diagnostics Company of the Year for the second consecutive year in the BioTech Breakthrough Awards. Its Merlin CP-GEP test was added to NCCN guidelines and received FDA Breakthrough Device Designation. The company also highlights its SKY92 test for multiple myeloma.PR NewswireSkylineDx Wins 2026 BioTech Breakthrough Award for "Diagnostics Company of the Year" for Second Consecutive YearSkylineDx won Diagnostics Company of the Year for the second consecutive year in the BioTech Breakthrough Awards. Its Merlin CP-GEP test was recognized in NCCN guidelines and received FDA Breakthrough Device Designation. The company also highlighted its SKY92 test for multiple myeloma.PR NewswireSkylineDx Expands Direct U.S. Commercial and Clinical Investment to Accelerate Access to Merlin™ CP-GEPSkylineDx completed its transition to a direct U.S. commercial model for Merlin CP-GEP, establishing a dedicated sales, marketing, and clinical organization of over 25 professionals. The expansion follows the test's inclusion in NCCN guidelines and FDA Breakthrough Device Designation, and the company plans to deepen clinical evidence and education as adoption grows.PR NewswireSkylineDx Expands Direct U.S. Commercial and Clinical Investment to Accelerate Access to Merlin™ CP-GEPSkylineDx completed its transition to a direct U.S. commercial model, establishing a dedicated sales, marketing, and clinical organization of over 25 professionals. The expansion follows Merlin CP-GEP's FDA Breakthrough Device Designation and NCCN Guidelines recognition. The company plans to deepen clinical evidence and education as adoption grows.citybizSkylineDx’s Merlin CP-GEP Earns FDA Breakthrough Device DesignationSkylineDx has received FDA Breakthrough Device Designation for its Merlin CP-GEP test designed to guide treatment decisions for patients with stage IB cutaneous melanoma. The designation recognizes the test's potential to improve metastatic risk assessment and is supported by findings from the MERLIN_001 clinical trial, the largest prospective study of its kind in cutaneous melanoma. The FDA's Breakthrough Devices Program is intended to accelerate the development and review of innovative medical technologies for life-threatening or debilitating diseases.Medical Device NetworkSkylineDX’s predictive melanoma test secures FDA breakthrough designationSkylineDX, a Dutch biotech company, announced that its Merlin clinicopathologic gene expression profile (CP-GEP) test for evaluating metastatic risk in early-stage cutaneous melanoma patients has received breakthrough device designation from the US Food and Drug Administration. The test, developed in partnership with Mayo Clinic, stratifies patients into high- or low-risk groups for metastases to inform surgical treatment decisions and is already available as a laboratory developed test in the US and Europe. The FDA designation is expected to accelerate the regulatory review process for commercialization.PR NewswireSkylineDx's Merlin CP-GEP Granted FDA Breakthrough Device Designation, Building on Exclusive NCCN Recognition in Melanoma CareSkylineDx, a biotechnology company headquartered in Rotterdam with operations in San Diego, announced that its Merlin CP-GEP gene expression profiling test for early-stage cutaneous melanoma received FDA Breakthrough Device Designation. The test, developed in collaboration with Mayo Clinic and already recognized in NCCN guidelines for T1b and T2a melanoma patients, is designed to support risk assessment and clinical decision-making including patient selection for sentinel lymph node biopsy procedures. The FDA designation, supported by data from the MERLIN_001 prospective multicenter clinical trial, is intended to expedite the development and review process for novel medical technologies addressing life-threatening or debilitating conditions.PR NewswireSkylineDx's Merlin CP-GEP Granted FDA Breakthrough Device Designation, Building on Exclusive NCCN Recognition in Melanoma CareSkylineDx announced the FDA granted Breakthrough Device Designation to Merlin CP-GEP, a gene expression profiling test for early-stage cutaneous melanoma. The test is already included in NCCN guidelines for T1b and T2a melanoma patients, supporting risk assessment and sentinel lymph node biopsy decisions.citybizSkylineDx Will Share Latest Cutaneous Squamous Cell Carcinoma Findings at 83rd SID ConferenceSkylineDx announced findings from two oral and one e-poster presentation on cutaneous squamous cell carcinoma at the 83rd Society for Investigative Dermatology Annual Meeting in Chicago, conducted as part of an international research collaboration with Erasmus Medical Center and University of California, San Francisco. The study represents the largest omics characterization of CSCC to date, involving RNA-sequencing of 366 tumors and whole-exome sequencing of 147 tumors, identifying biomarkers associated with poor prognosis and genetic alterations in HLA class I genes. The company also introduced SCCore GEP, a novel gene expression signature designed to improve metastatic risk stratification beyond traditional staging systems, particularly for the one-third of metastases occurring in patients initially classified as low-risk.